<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">29759659</PMID>        <DateRevised>            <Year>2018</Year>            <Month>07</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1440-1592</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>67</Volume>                    <Issue>3</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Jul</Month>                    </PubDate>                </JournalIssue>                <Title>Allergology international : official journal of the Japanese Society of Allergology</Title>                <ISOAbbreviation>Allergol Int</ISOAbbreviation>            </Journal>            <ArticleTitle>The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseases.</ArticleTitle>            <Pagination>                <MedlinePgn>301-308</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S1323-8930(18)30048-0</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.alit.2018.03.008</ELocationID>            <Abstract>                <AbstractText>Allergy immunotherapy (AIT) is a treatment option for respiratory allergy that is complementary to pharmacotherapy, with a distinct mechanism of action. Alternative methods to subcutaneous administration of AIT that enable patients to safely self-administer AIT is considered an unmet clinical need. The sublingual immunotherapy tablet (SLIT-tablet) is an orally disintegrating pharmaceutical formulation (oral lyophilisate) containing standardized allergens. SLIT-tablets have been developed for sublingual immunotherapy (SLIT) of cedar-pollen, grass-pollen, ragweed-pollen, tree-pollen, and house dust mite allergies. It is a once-daily tablet treatment to be self-administered after the first dose has been provided under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases. Once the first dose is adequately tolerated, subsequent doses may be self-administered. SLIT-tablets have proven efficacy for allergic rhinitis (AR) with and without conjunctivitis (C) and allergic asthma (AA) in adults, children, and poly-sensitized allergic patients. Meta-analyses indicate that SLIT-tablets have superior or similar efficacy compared with anti-allergic pharmacotherapies for seasonal AR and superior efficacy for perennial AR. SLIT-tablets have also demonstrated clinically relevant improvements of asthma, with significant reductions in the following: daily inhaled corticosteroid use, risk of asthma exacerbations, and asthma symptoms. SLIT-tablets are generally well tolerated, with a low risk of systemic allergic reactions. The most common treatment-related adverse events are mild-moderate oral reactions. Current evidence supports SLIT-tablets to be considered as an alternative or add-on treatment to pharmacotherapy for AR/C and asthma. Future SLIT developments may include early intervention to prevent the development or progression of allergic disease in children.</AbstractText>                <CopyrightInformation>Copyright © 2018 Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Nolte</LastName>                    <ForeName>Hendrik</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>ALK, Hørsholm, Denmark. Electronic address: Hendrik.nolte@alk.net.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Maloney</LastName>                    <ForeName>Jennifer</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>ALK, Hørsholm, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>05</Month>                <Day>16</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Allergol Int</MedlineTA>            <NlmUniqueID>9616296</NlmUniqueID>            <ISSNLinking>1323-8930</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Allergic rhinitis</Keyword>            <Keyword MajorTopicYN="N">Asthma</Keyword>            <Keyword MajorTopicYN="N">Rhinoconjunctivitis</Keyword>            <Keyword MajorTopicYN="N">SLIT</Keyword>            <Keyword MajorTopicYN="N">Sublingual immunotherapy</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>26</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>03</Month>                <Day>16</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>5</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>5</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>5</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">29759659</ArticleId>            <ArticleId IdType="pii">S1323-8930(18)30048-0</ArticleId>            <ArticleId IdType="doi">10.1016/j.alit.2018.03.008</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>